Edwards Lifesciences Corporatio
EW
Positions held
Your positionsEW isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Edwards Lifesciences is well-positioned in the growing medical devices industry, focusing on innovative heart valve therapies that address significant unmet needs.
- Revenue increased by 6% compared to the prior quarter, reaching $1.7 billion.
- The company maintains a strong gross margin of 77.5%, indicating efficient production and pricing strategies.
- Despite its market potential, Edwards Lifesciences faces challenges with a declining earnings growth rate, which can affect investor confidence.
- Net income dropped to $241.9 million in Q2 2026, down from $380.7 million in Q1 2026.
- The current score indicates a 'Sell' signal with a score of -5.00, reflecting negative trends in market performance.
Fundamentals
| Market cap | $48.56B | Enterprise value | $45.11B | Trailing P/E | 50.14 | Forward P/E | 24.90 |
| PEG | 1.83 | Price / book | 4.57 | Beta | 0.86 | Dividend yield | 0.00% |
| Revenue growth | 13.6% | Earnings growth | -25.4% | Gross margin | 77.8% | Operating margin | 29.8% |
| Profit margin | 15.4% | ROE | 9.2% | ROA | 8.4% | Debt / equity | 0.07 |
| Current ratio | 4.52 | Free cash flow | $1.23B | Analyst recommendation | buy | Mean target | $101.96 |
| 52w high | $96.29 | 52w low | $72.30 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.6B | $1.6B | $1.6B | $1.5B | — |
| Op margin | 29.8% | 31.2% | 23.6% | 27.4% | 28.1% | — |
| Net income | $242M | $381M | $91.2M | $291M | $333M | — |
| Gross margin | 77.5% | 78.0% | 78.1% | 77.8% | 77.5% | — |
| Gross profit | $1.3B | $1.3B | $1.2B | $1.2B | $1.2B | — |
| Operating income | $520M | $515M | $370M | $425M | $431M | — |
- Revenue +6% vs prior quarter ($1.7B vs $1.6B).
- Gross margin 77.5% (was 78% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.1B | $5.4B | $5.0B | $4.5B | — |
| Op margin | 27.0% | 27.2% | 29.7% | 34.5% | — |
| Net income | $1.1B | $4.2B | $1.4B | $1.5B | — |
| Gross margin | 78.0% | 79.5% | 80.5% | 83.8% | — |
| Gross profit | $4.7B | $4.3B | $4.0B | $3.7B | — |
| Operating income | $1.6B | $1.5B | $1.5B | $1.5B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-07 · Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
2026-10-05 · Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating
2026-10-05 · Edwards Lifesciences to Host Investor Event in Conjunction With TCT
2026-10-02 · JPMorgan Adjusts Price Target on Edwards Lifesciences to $105 From $100, Keeps Overweight Rating
2026-10-01 · Edwards Lifesciences Says US FDA Approves AUTUS Pediatric Pulmonary Valve
2026-10-01 · Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
2026-09-18 · How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions
2026-09-18 · Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion
2026-09-18 · Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031
Price (daily)
Full chart · RSI · MACD · patternsChart patterns
Actionable setups from the latest nightly S&P 500 scan.
- 71%
Descending Triangle
bearish
- Completed
- Sep 30, 2026
- Trigger
- 85.07
Converging 71% over 21 bars; 6 pivots on 2 trendlines
View on chart →